Todays Report: The Quantitative Systematic Strategies LLC Acquires 49,852 Shares of Clovis Oncology Inc. (CLVS)

The Quantitative Systematic Strategies LLC Acquires 49,852  Shares of Clovis Oncology Inc. (CLVS)

Quantitative Systematic Strategies LLC purchased a new stake in shares of Clovis Oncology Inc. (NASDAQ:CLVS) during the second quarter, Holdings Channel reports. The firm purchased 49,852 shares of the biopharmaceutical company’s stock, valued at approximately $751,000.

Several other institutional investors have also made changes to their positions in CLVS. Fox Run Management L.L.C. bought a new position in shares of Clovis Oncology during the second quarter valued at $154,000. CIBC World Markets Inc. boosted its position in shares of Clovis Oncology by 7.8% in the first quarter. CIBC World Markets Inc. now owns 11,680 shares of the biopharmaceutical company’s stock valued at $224,000 after buying an additional 850 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of Clovis Oncology during the first quarter valued at $233,000. Kazazian Asset Management LLC bought a new position in shares of Clovis Oncology during the first quarter valued at $282,000. Finally, Candriam Luxembourg S.C.A. boosted its position in shares of Clovis Oncology by 46.9% in the second quarter. Candriam Luxembourg S.C.A. now owns 47,000 shares of the biopharmaceutical company’s stock valued at $645,000 after buying an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 98.46% of the company’s stock.

Clovis Oncology Inc. (NASDAQ:CLVS) traded up 1.778% on Thursday, reaching $33.261. The company’s stock had a trading volume of 1,504,409 shares. The stock’s market capitalization is $1.28 billion. The firm has a 50 day moving average price of $30.54 and a 200 day moving average price of $18.97. Clovis Oncology Inc. has a 52 week low of $11.57 and a 52 week high of $109.18.

Clovis Oncology (NASDAQ:CLVS) last issued its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($2.13) by $0.06. During the same quarter in the previous year, the firm earned ($2.10) EPS. On average, equities analysts anticipate that Clovis Oncology Inc. will post ($9.25) EPS for the current year.

Several research analysts have recently weighed in on CLVS shares. SunTrust Banks Inc. boosted their target price on Clovis Oncology from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, September 23rd. Zacks Investment Research cut Clovis Oncology from a “buy” rating to a “hold” rating in a report on Tuesday, October 4th. Credit Suisse Group AG restated an “outperform” rating and set a $41.00 target price on shares of Clovis Oncology in a report on Monday. Piper Jaffray Cos. restated a “neutral” rating and set a $14.00 target price on shares of Clovis Oncology in a report on Thursday, August 25th. Finally, Janney Montgomery Scott cut Clovis Oncology from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $35.00 to $36.00 in a report on Wednesday, September 21st. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $36.39.

Clovis Oncology Company Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M.

Related posts

Leave a Comment